The Future of Genomic Diagnostics
Advancing Precision Medicine
with Accessible NGS Solutions
The Foresee Genomics Advantage
Integrated Solution
Innovative molecular kit with cutting edge software for seamless operation
Precision Sequencing
Highly accurate sequencing using Nanopore technology, ensuring reliable results
Proven Technology
Validated technology, ensuring trust and reliability
Rapid Scalability
Flexible solutions tailored to small and medium-sized labs
Professional Standards
Tailored for CLIA/ISO15189 certified labs, an ideal choice for Laboratory Developed Tests (LDT)
User-Centric Design
Designed for customer ease and usability
Fast, Affordable and High-Precision NGS Solutions
Foresee Genomics is transforming genomic testing with our innovative Next Generation Sequencing (NGS) solutions. By combining proprietary molecular biology and bioinformatics software with fourth generation Nanopore sequencing technology, we empower small and medium labs to deliver fast, affordable and highly accurate diagnostics.
Re-envisioning NGS for Small-Medium Labs
Foresee Genomics simplifies and accelerates the NGS workflow to provide small- and medium-sized labs with access to life-changing information to drive precision medicine forward. We provide NGS in a manner that is more affordable, with faster results, and the ability to run at lower volumes, making it ideal for clinical diagnostics in a small or medium lab setting.
Integrated
Molecular Kits
Streamlined sample preparation with user-friendly protocols
Sequencing
Technology
Real-time, high-accuracy sequencing adaptable for various diagnostic needs
Proprietary
Analysis Software
Automated data interpretation for actionable clinical insights
VALIDATED TECHNOLOGY
Foresee Genomics’ technology platform, SeqF, has been validated in numerous independent runs and
samples to deliver high-precision, accurate and reproducible results.
Comparisons with expected allele frequencies in synthetic and spiked samples, together with observed
allele frequencies from independent sequencing platforms (MiSeq and MGI) indicate the high accuracy and sensitivity of SeqF deployed with the MinION platform.
The figure presents an example of SeqF’s performance showcasing the identification of the IDH2 R172K mutation in the HD829 standard across three sequencing platforms, compared with the expected allele frequency.
SeqF consistently aligns with expected VAF, indicating its
capability in detecting low-frequency mutations in cancer genomics and precision medicine.
Foresee Genomics Provides Highly Accurate and Consistent Mutation Detection
Comparing Mutation Detection Across Sequencing Platforms
